Long-Term Miglustat Therapy in Children With Niemann-Pick Disease Type C

Niemann-Pick disease type C is a rare, genetic disease associated with impaired intracellular lipid trafficking and progressive neurological symptoms. Miglustat slowed disease progression in a 12-month randomized trial in juveniles and adults with Niemann-Pick disease type C, and in a parallel, nonc...

Full description

Saved in:
Bibliographic Details
Published in:Journal of child neurology 2010-03, Vol.25 (3), p.300-305
Main Authors: Patterson, Marc C., Vecchio, Darleen, Jacklin, Elizabeth, Abel, Larry, Chadha-Boreham, Harbajan, Luzy, Cecile, Giorgino, Ruben, Wraith, James E.
Format: Article
Language:English
Subjects:
1-Deoxynojirimycin - administration & dosage
1-Deoxynojirimycin - adverse effects
1-Deoxynojirimycin - analogs & derivatives
1-Deoxynojirimycin - therapeutic use
Child
Child, Preschool
Deglutition - drug effects
Enzyme Inhibitors - administration & dosage
Enzyme Inhibitors - adverse effects
Enzyme Inhibitors - therapeutic use
Female
Humans
Male
Motor Activity - drug effects
Niemann-Pick Disease, Type C - drug therapy
Prospective Studies
Saccades - drug effects
Time Factors
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Niemann-Pick disease type C is a rare, genetic disease associated with impaired intracellular lipid trafficking and progressive neurological symptoms. Miglustat slowed disease progression in a 12-month randomized trial in juveniles and adults with Niemann-Pick disease type C, and in a parallel, noncontrolled study in affected children. Here, the authors report the open-label extension to the pediatric study. Patients aged 4 to 12 years received open-label miglustat (dose adjusted for body surface area) for an initial 12 months, during a further 12-month extension, and a long-term, continued extension phase. Efficacy assessments included horizontal saccadic eye movement, swallowing, and ambulation. Ten children completed 24 months’ treatment. Horizontal saccadic eye movement, ambulation, and swallowing were stabilized at 24 months. Analysis of key parameters of disease progression showed disease stability in 8 of 10 patients (80%). Miglustat stabilized neurological disease progression in pediatric patients with Niemann-Pick disease type C, with comparable safety and tolerability to that observed in adults and juveniles.
ISSN:0883-0738
1708-8283
DOI:10.1177/0883073809344222